Here’s why Tyro Payments (ASX:TYR) rose as much as 20% today
Nick Sundich, August 29, 2023
Tyro Payments (ASX:TYR) was the best performer amongst stocks that released FY23 results today.
What are the Best Tech stocks to invest in right now?
Check our buy/sell stock tips
Tyro Payments (ASX:TYR) delivers a good FY23 result
Tyro Payments is a EFTPOS terminal provider and is the largest non-Big Bank provider. It generated 25% growth in transaction value (to $42.6bn), a 32% increase in revenues (to $419.2m) and gross profit (to $204.3m), as well as a bottom line profit of $6m (from -$29.6m the year before).
This was the first full-year positive cash flow result as a publicly listed company.
Slower growth in FY24, but…
For FY254, Tyro guided to $45-$47.5bn transaction value and $206-$215m gross profit.
Even though both figures would represent slower growth than the year before, it seems investors were happy that it was immune to inflation, that the company’s new operating model was paying off and most importantly, that terminal outages and the subsequent furore from customers appears over.
Stocks Down Under Concierge is here to help you pick winning stocks!
The team at Stocks Down Under have been in the markets since the mid-90s and we have gone through many ups and downs. We have written about every sector, including Semiconductors!
Our Concierge BUY and SELL service picks the best stocks on ASX. We won’t just tell you what to buy – we give you a buy range, price target and stop loss level in order to maximise total returns. And we will only recommend very high conviction stocks where substantial due diligence has been conducted.
Our performance is well ahead of the ASX200 and All Ords.
You can try out Concierge … for FREE.
GET A FREE TRIAL TO CONCIERGE TODAY
There’s no credit card needed – the trial expires automatically.
Blog Categories
Get Our Top 5 ASX Stocks for FY26
Recent Posts
Prescient Therapeutics (ASX:PTX): Its taken the plunge into a Phase 2 trial against T-Cell Lymphoma
There’s plenty of ASX oncology biotechs conducting clinical trials, but Prescient Therapeutics (ASX:PTX) is one of the closest to commercialisation.…
Botanix Pharmaceuticals (ASX:BOT): Did it deserve to crash over 50% earlier this week?
Botanix Pharmaceuticals (ASX:BOT) crashed over 50% back on Tuesday after an update that left investors disappointed. A crash of this…
How can an investor beat the market? Here’s how to go about it
You may’ve heard the expression to ‘beat the market’. What does this mean? Well, it depends on the context in…